Article

Single-cell foundation models predict durable CAR T response despite imperfect cell annotation

2026-07-23

Abstract excerpt

CD19-targeted chimeric antigen receptor (CAR) T cell therapy achieves high initial response rates in B-cell acute lymphoblastic leukemia (B-ALL), yet half of patients relapse within one year. Pre-infusion product composition decoded by single-cell RNA sequencing (scRNA-seq) carries information predictive of long-term CAR T persistence, but extracting this information from individual patients typically requires hig...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c251ece6-6df6-5ba4-a3c7-e678eed0f90b
DOI: 10.64898/2026.07.22.740224

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Single-cell foundation models predict durable CAR T response despite imperfect cell annotationDOI 10.64898/2026.07.22.740224Read

Single-cell foundation models predict durable CAR T response despite imperfect cell annotationSemantic proximity Read

CART-GPT: A T Cell-Informed AI Linguistic Framework for Interpreting Neurotoxicity and Therapeutic Outcomes in CAR-T TherapySemantic proximity Read

Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma PatientsSemantic proximity Read

Functional diversification and dynamics of CAR-T cells in patients with B-ALLSemantic proximity Read

Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALLSemantic proximity Read

Common trajectories of highly effective CD19-specific CAR T cells identified by endogenous T cell receptor lineagesSemantic proximity Read

Distinct cellular dynamics associated with response to CAR-T therapy for refractory B-cell lymphomaSemantic proximity Read

Integrative single-cell multi-omics of CD19-CAR <sup>pos</sup> and CAR <sup>neg</sup> T cells suggest drivers of immunotherapy response in B-cell neoplasiasSemantic proximity Read

Deconvolution of clinical variance in CAR-T cell pharmacology and responseSemantic proximity Read

CAR+ and CAR− T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignanciesSemantic proximity Read

Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologiesSemantic proximity Read

Single-cell antigen-specific activation landscape of CAR T infusion product identifies determinants of CD19 positive relapse in patients with ALLSemantic proximity Read